3 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMOWill not start
Study goal is to compare the performance of the Absorb bioresorbable scaffold with a metallic drug eltuting stent in the STEMI patient.
Approved WMORecruiting
The purpose of the current investigation is therefore to prove the short-term equivalence and long-term benefit of the ABSORB scaffold over a Xience in patients at high risk of restenosis or with complex lesion(s).Diabetic substudyTo assess theā¦